FibroGen (NASDAQ:FGEN) Sees Large Volume Increase

FibroGen, Inc. (NASDAQ:FGEN) shares saw unusually-high trading volume on Thursday . Approximately 60,416 shares traded hands during trading, a decline of 95% from the previous session’s volume of 1,252,101 shares.The stock last traded at $18.95 and had previously closed at $19.74.

FGEN has been the subject of several research analyst reports. Mizuho cut FibroGen from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $72.00 to $29.00 in a research report on Wednesday. Bank of America upgraded FibroGen from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Wednesday, March 31st. SVB Leerink decreased their price target on FibroGen from $64.00 to $56.00 and set an “outperform” rating on the stock in a research report on Wednesday. HC Wainwright lowered FibroGen from a “buy” rating to a “neutral” rating in a research report on Wednesday. Finally, Raymond James restated a “sell” rating on shares of FibroGen in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $46.14.

The stock has a market capitalization of $1.74 billion, a P/E ratio of -7.56 and a beta of 1.59. The stock has a 50-day simple moving average of $38.93 and a 200 day simple moving average of $42.24.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Sunday, February 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.35). The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $100.82 million. FibroGen had a negative net margin of 191.78% and a negative return on equity of 48.19%. The business’s revenue for the quarter was up 712.5% compared to the same quarter last year. During the same period last year, the company earned ($1.12) EPS. As a group, equities analysts forecast that FibroGen, Inc. will post -1.72 EPS for the current year.

In related news, Director Thomas F. Kearns, Jr. sold 18,000 shares of the firm’s stock in a transaction on Thursday, March 11th. The stock was sold at an average price of $35.02, for a total transaction of $630,360.00. Following the sale, the director now owns 166,164 shares of the company’s stock, valued at approximately $5,819,063.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kalevi Kurkijarvi sold 6,000 shares of the firm’s stock in a transaction on Tuesday, January 19th. The stock was sold at an average price of $43.38, for a total value of $260,280.00. Following the sale, the director now directly owns 39,100 shares in the company, valued at approximately $1,696,158. The disclosure for this sale can be found here. In the last three months, insiders sold 35,999 shares of company stock worth $1,445,240. 3.39% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Pacer Advisors Inc. grew its holdings in shares of FibroGen by 17.3% in the 4th quarter. Pacer Advisors Inc. now owns 3,228 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 476 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of FibroGen by 4.7% in the 4th quarter. Victory Capital Management Inc. now owns 11,130 shares of the biopharmaceutical company’s stock valued at $413,000 after acquiring an additional 501 shares in the last quarter. Aperio Group LLC grew its holdings in shares of FibroGen by 4.2% in the 4th quarter. Aperio Group LLC now owns 13,161 shares of the biopharmaceutical company’s stock valued at $488,000 after acquiring an additional 527 shares in the last quarter. Tygh Capital Management Inc. grew its holdings in shares of FibroGen by 1.2% in the 4th quarter. Tygh Capital Management Inc. now owns 48,675 shares of the biopharmaceutical company’s stock valued at $1,805,000 after acquiring an additional 569 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in shares of FibroGen by 24.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,545 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 700 shares in the last quarter. Institutional investors own 75.05% of the company’s stock.

FibroGen Company Profile (NASDAQ:FGEN)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Story: Trading Stocks – What are percentage gainers?

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.